On the basis of several preclinical studies, cell-based therapy has emerged as a potential
new therapeutic for acute respiratory distress syndrome (ARDS). Of the various cell-based …

The acute respiratory distress syndrome (ARDS) is a multifaceted lung disorder in which no
specific therapeutic intervention is able to effectively improve clinical outcomes. Despite an …

Acute respiratory distress syndrome (ARDS) is driven by a severe pro-inflammatory
response resulting in lung damage, impaired gas exchange and severe respiratory failure …

Morbidity and mortality have declined only modestly in patients with clinical acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the …

Acute respiratory distress syndrome (ARDS) is a devastating hypoxemic respiratory failure,
characterized by disruption of the alveolar-capillary membrane barrier. Current management …

Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …

Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic
effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis …

A growing understanding of the complexity of the pathophysiology of acute lung injury
(ALI)/acute respiratory distress syndrome (ARDS), coupled with advances in stem cell …

Objectives: Mesenchymal stem cells–based therapies have shown promising effects in
experimental acute respiratory distress syndrome. Different mesenchymal stem cells …

Despite extensive research into the pathogenesis of acute lung injury and the acute
respiratory distress syndrome (ALI/ARDS), mortality remains high at approximately 40 …